Oncology Startups & Innovation Watchlist
Tracking the emerging companies transforming global cancer care
The future of cancer treatment is being shaped by a new generation of oncology startups advancing immunotherapy, liquid biopsies, AI-powered diagnostics, genomic editing, radiopharmaceuticals, and personalized medicine. Our Innovation Watchlist highlights the most promising early-stage and mid-stage companies developing breakthrough technologies with the potential to redefine cancer detection, monitoring, and treatment.
Immunotherapy & Cell Therapy
USA
Focus:
CAR-T & engineered T-cell therapies
Why it matters:
Developing next-gen T-cell treatments with improved safety and reduced cytokine release.
Germany
Focus:
TCR-based immunotherapies
Why it matters:
Targeting solid tumors with precision-engineered T-cell receptors.
USA/Netherlands
Focus:
Personalized TCR therapies
Why it matters:
Acquired by AstraZeneca for its groundbreaking neoantigen identification technology.
Genomic Medicine & Precision Oncology
USA
Focus:
AI-driven genomic sequencing
Why it matters:
One of the most comprehensive cancer informatics platforms globally.
USA
Focus:
Liquid biopsies
Why it matters:
Leading blood-based early detection for multiple cancer types.
China/USA
Focus:
Methylation-based early detection
Why it matters:
Competing with Grail in global multi-cancer early detection.
USA
Focus:
Network-based precision oncology from UCSF
Why it matters:
Innovative approach to understanding cancer networks.
AI-Powered Diagnostics & Imaging
USA
Focus:
AI pathology
Why it matters:
Improves diagnostic accuracy and speeds up pathology review.
France/USA
Focus:
Federated oncology AI
Why it matters:
$200M investment from Sanofi; used for clinical trial prediction & biomarker discovery.
China
Focus:
AI radiology
Why it matters:
Regulatory-cleared AI systems for lung and breast cancer detection.
USA
Focus:
Protein detection platform with ultra-high sensitivity
Why it matters:
Revolutionary sensitivity in protein biomarker detection.
Radiopharmaceutical & Theranostics
Canada
Focus:
Targeted alpha therapies
Why it matters:
Pioneering radiopharmaceuticals for prostate and breast cancer.
USA
Focus:
Precision radiopharmaceuticals
Why it matters:
Recently acquired for its groundbreaking work in peptide-based targeted therapies.
USA/Canada
Focus:
Targeted radionuclide therapy
Why it matters:
Late-stage radiopharmaceutical trials gaining global attention.
Early Detection & Screening
USA
Focus:
Multi-cancer early detection test
Why it matters:
Can detect 50+ cancers through a single blood test.
USA
Focus:
Early-stage detection using multi-omics
Why it matters:
Blood-based detection platform for colorectal and other cancers.
Hong Kong/UK
Focus:
Multi-omics & early detection
Why it matters:
Strong presence in Asia & expanding global oncology pipeline.
Minimal Residual Disease (MRD) Monitoring
USA
Focus:
ctDNA-based MRD testing
Why it matters:
Industry leader in early recurrence detection.
USA/China
Focus:
Liver cancer ctDNA MRD
Why it matters:
Strong results in high-incidence hepatocellular carcinoma (HCC) markets.
Microbiome & Oncolytic Virus
Australia
Focus:
Microbiome-based immunotherapy assistance
Why it matters:
Modulating the gut influences immunotherapy success.
USA
Focus:
Oncolytic viruses for bladder cancer
Why it matters:
FDA fast-track and strong early data.
Emerging - Ones to Watch
USA
Focus:
Network-based precision oncology from UCSF
Why it matters:
Innovative approach to understanding cancer networks.
USA
Focus:
Targeting RAS mutations
Why it matters:
Huge commercial potential in historically 'undruggable' targets.
USA
Focus:
Protein detection platform with ultra-high sensitivity
Why it matters:
Revolutionary sensitivity in protein biomarker detection.
USA
Focus:
Drug development platform built out of Battelle
Why it matters:
Accelerating oncology drug development timelines.
Coming Soon - Additional Innovation Categories
Gene editing & CRISPR oncology
Wearable cancer monitoring
Nanomedicine
Robotics in surgery
Digital therapeutics
Real-world evidence (RWE) analytics
Psychedelic-assisted treatments for cancer distress
